June 2nd 2021
By Tony Hagen
Real-world clinical data compiled for patients with autoimmune disorders were presented at EULAR 2021.
Celltrion announces the launch timing for its much anticipated high-concentration formulation of adalimumab and presents trial data supporting equivalence to the reference product.
June 1st 2021
Biosimilar manufacturers may encounter roadblocks in the months and years ahead, and generics manufacturers will find they've hit a ceiling, according to Adam Fein, PhD, CEO of the Drug Channels Institute.
May 28th 2021
More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.
May 20th 2021
A study funded by AbbVie finds support for maintaining patients on originator rheumatic agents, such as Humira (adalimumab), rather than switching to biosimilars.
May 18th 2021
Accused of unfair trade practices, AbbVie's CEO Richard Gonzalez pointed the finger at Medicare Part D.
The House Committee on Oversight and Reform contends AbbVie's "biosimilar defense strategy" has succeeded beyond the company's wildest imagination.
May 17th 2021
Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).
May 11th 2021
After being sued for allegedly stealing adalimumab process information, Alvotech fires back.
By Deana Ferreri, PhD
Investigators ranked biologics and Janus kinase 1 inhibitors based on past findings.
